Optimising therapeutic options for patients with advanced pancreatic neuroendocrine tumours

European Oncology and Haematology

Volumn 8, Issue 4, 2012, Pages 217-223

  Yao, James ^a   Phan, Alexandria T ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Everolimus; Pancreatic neuroendocrine tumour; pNET; RADIANT 1; RADIANT 3; Somatostatin analogues; Streptozocin based chemotherapy; Sunitinib

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CHLOROZOTOCIN; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; LUTETIUM 177; LUTETIUM TETRAXETAN OCTREOTATE LU 177; OCTREOTIDE; PLACEBO; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; YTTRIUM 90; YTTRIUM TETRAXETAN PHENYLALANINE 1 TYROSIN 3 ORTREOTIDE Y 90;

ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC KIDNEY FAILURE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; INFECTION; INFECTIOUS PNEUMONIA; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LEUKOPENIA; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PNEUMONIA; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 84873256918     PISSN: 20455275     EISSN: 20455283     Source Type: Journal    
DOI: 10.17925/eoh.2012.08.4.217     Document Type: Article

References (56)

1. Oberg KE, The Management of Neuroendocrine Tumours: Current and Future Medical Therapy Options, Clin Oncol (R Coll Radiol), 2012;24:282-93.
2. Yao JC, Eisner MP, Leary C, et al., Population-based study of islet cell carcinoma, Ann Surg Oncol, 2007;14:3492-500.
3. Eriksson B, Oberg K, Neuroendocrine tumours of the pancreas, Br J Surg, 2000;87:129-31.
4. Lam KY, Lo CY, Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature, Eur J Surg Oncol, 1997;23:36-42.
5. Oberg K, Castellano D, Current knowledge on diagnosis and staging of neuroendocrine tumors, Cancer Metastasis Rev, 2011;30(Suppl. 1):3-7.
6. Yao JC, Hassan M, Phan A, et al., One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States, J Clin Oncol, 2008a;26:3063-72.
7. Kulke MH, Bendell J, Kvols L, et al., Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors, J Hematol Oncol, 2011;4:29.
8. Jiao Y, Shi C, Edil BH, et al., DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors, Science, 2011;331:1199-203.
9. Wu T, Hua X, Menin represses tumorigenesis via repressing cell proliferation, Am J Cancer Res, 2011;1:726-39.
10. Heaphy CM, de Wilde RF, Jiao Y, et al., Altered telomeres in tumors with ATRX and DAXX mutations, Science, 2011;333:425.
11. Populo H, Lopes JM, Soares P, The mTOR Signalling Pathway in Human Cancer, Int J Mol Sci, 2012;13:1886-918.
12. Kvols LK, Buck M, Moertel CG, et al., Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995), Ann Intern Med, 1987;107:162-8.
13. Kraenzlin ME, Ch'ng JL, Wood SM, et al., Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases, Gastroenterology, 1985;88:185-7.
14. Shojamanesh H, Gibril F, Louie A, et al., Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma, Cancer, 2002;94:331-43.
15. Rosenbaum A, Flourie B, Chagnon S, et al., Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature, Digestion, 1989;42:116-20.
16. Rinke A, Muller HH, Schade-Brittinger C, et al., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group, J Clin Oncol, 2009;27:4656-63.
17. Falconi M, Bartsch DK, Eriksson B, et al., ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors, Neuroendocrinology, 2011;95:120-34.
18. Kouvaraki MA, Ajani JA, Hoff P, et al., Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas, J Clin Oncol, 2004;22:4762-71.
19. McCollum AD, Kulke MH, Ryan DP, et al., Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors, Am J Clin Oncol, 2004;27:485-8.
20. Moertel CG, Lefkopoulo M, Lipsitz S, et al., Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma, N Engl J Med, 1992;326:519-23.
21. Yao JC, Lombard-Bohas C, Baudin E, et al., Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial, J Clin Oncol, 2010;28:69-76.
22. Yao JC, Phan AT, Chang DZ, et al., Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study, J Clin Oncol, 2008b;26:4311-8.
23. Kulke MH, Bergsland EK, Yao JC, Glycemic control in patients with insulinoma treated with everolimus, N Engl J Med, 2009a;360:195-7.
24. Kulke MH, Hornick JL, Frauenhoffer C, et al., O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors, Clin Cancer Res, 2009b;15:338-45.
25. Ekeblad S, Sundin A, Janson ET, et al., Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors, Clin Cancer Res, 2007;13:2986-91.
26. Strosberg JR, Fine RL, Choi J, et al., First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas, Cancer, 2010;117:268-75.
27. Kulke MH, Stuart K, Earle CC, et al., A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors, J Clin Oncol, 2006a;24:18S,4044.
28. Kulke MH, Stuart K, Enzinger PC, et al., Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors, J Clin Oncol, 2006b;24:401-6.
29. Kulke MH, Blaszkowsky LS, Zhu AX, et al., Phase I/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET), Gastrointestinal Cancers Symposium, 2010;Abstract 223.
30. Yao JC, Shah MH, Ito T, et al., Everolimus for advanced pancreatic neuroendocrine tumors, N Engl J Med, 2011;364:514-23.
31. Kulke MH, Lenz HJ, Meropol NJ, et al., Activity of sunitinib in patients with advanced neuroendocrine tumors, J Clin Oncol, 2008;26:3403-10.
32. Raymond E, Niccoli P, Raoul J, et al., Updated overall survival and progression-free survival by blinded independent central review of sunitinib versus placebo for patients with advanced unresectable pancreatic neuroendocrine tumours, J Clin Oncol, 2011b;29:Abstract 4008.
33. Raymond E, Dahan L, Raoul JL, et al., Sunitinib malate for the treatment of pancreatic neuroendocrine tumors, N Engl J Med, 2011a;364:501-13.
34. Imhof A, Brunner P, Marincek N, et al., Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers, J Clin Oncol, 2011;29:2416-23.
35. Kwekkeboom DJ, de Herder WW, Kam BL, et al., Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival, J Clin Oncol, 2008;26:2124-30.
36. Strosberg JR, Choi J, Cantor AB, et al., Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors, Cancer Control, 2006;13:72-8.
37. Marrache F, Vullierme MP, Roy C, et al., Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours, Br J Cancer, 2007;96:49-55.
38. King J, Quinn R, Glenn DM, et al., Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases, Cancer, 2008;113:921-9.
39. Rhee TK, Lewandowski RJ, Liu DM, et al., 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience, Ann Surg, 2008;247:1029-35.
40. Kennedy AS, Dezarn WA, McNeillie P, et al., Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients, Am J Clin Oncol, 2008;31:271-9.
41. Signorovitch JE, Swallow E, Kantor E, et al., Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of clinical trials, J Clin Oncol, 2012;30(suppl.);abstract e14621.
42. De Vries EG, Anthony LB, Sideris L, et al., Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results, J Clin Oncol, 2011;29(suppl.);abstract 10624.
43. Blumenthal GM, Cortazar P, Zhang JJ, et al., FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors, Oncologist, 2012;17(8):1108-13.
44. Chu TF, Rupnick MA, Kerkela R, et al., Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib, Lancet, 2007;370:2011-9.
45. Waldherr C, Pless M, Maecke HR, et al., The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study, Ann Oncol, 2001;12:941-5.
46. Cwikla JB, Sankowski A, Seklecka N, et al., Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study, Ann Oncol, 2010;21:787-94.
47. Mayo SC, de Jong MC, Pulitano C, et al., Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis, Ann Surg Oncol, 2010;17:3129-36.
48. Dousset B, Saint-Marc O, Pitre J, Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation, World J Surg, 1996;20:908-14.
49. Sarmiento JM, Heywood G, Rubin J, et al., Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival, J Am Coll Surg, 2003;97:29-37.
50. Gulati AP, Saif MW, Is There a Role for Liver Transplantation in Metastatic Pancreatic Neuroendocrine Tumors (PNET)?, JOP, 2012;13:320-1.
51. Lehnert T, Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients, Transplantation, 1998;66:1307-12.
52. Le Treut YP, Delpero JR, Dousset B, et al., Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report, Ann Surg, 1997;225:355-64.
53. Alistar A, Sung M, Kim M, et al., Clinical Pathways for Pancreatic Neuroendocrine Tumors, J Gastrointest Cancer, 2012; in press.
54. Ruszniewski P, Rougier P, Roche A, et al., Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients, Cancer, 1993;71:2624-30.
55. Lewis MA, Jaramillo S, Roberts L, et al., Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications, Oncologist, 2012;17:725-31.
56. Falconi M, Bartsch DK, Eriksson B, et al., ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors, Neuroendocrinology, 2012;95:120-34.